Symphony GenIsis Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 2

Symphony GenIsis General Information

Description

Developer of cholesterol-lowering and diabetic drugs. The company's clinical programs include ISIS 301012, an antisense drug, which inhibits a protein for the synthesis and transport of the bad cholesterol involved in heart disease; Glucagon receptor, a cellular receptor for glucagon, one of the counter-regulatory hormones that oppose the action of insulin and helps maintain normal blood glucose levels; and The glucocorticoid receptor, which is an intracellular protein that serves as the receptor for the steroid hormones of the glucocorticoid family. The company operates as a subsidiary of ISIS Pharmaceuticals.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Food Products
Primary Office
  • 7361 Calhoun Place
  • Suite 325
  • Rockville, MD 20855
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Symphony GenIsis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Symphony GenIsis‘s full profile, request access.

Request a free trial

Symphony GenIsis Executive Team (1)

Name Title Board Seat Contact Info
Neil Sandler Founding Partner
To view Symphony GenIsis’s complete executive team members history, request access »

Symphony GenIsis Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Symphony GenIsis‘s full profile, request access.

Request a free trial